Srivathsan Komandoor, Showalter John, Wilkens James, Hurley Brian, Abbas Amr, Loutfi Hassan
Division of Cardiovascular Diseases and Hospital Internal Medicine, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.
Int J Cardiol. 2004 Nov;97(2):221-4. doi: 10.1016/j.ijcard.2003.08.018.
Among patients with acute coronary syndrome, elevated cardiac troponin and creatine phosphokinase MB fraction levels have both prognostic and diagnostic values. However, in hospitalized patients, cardiac biomarkers are measured in a variety of clinical situations including but not limited to acute coronary syndrome. Moreover, these patients may have elevated troponin levels with no increase in creatine phosphokinase MB fraction levels.
To evaluate the cardiovascular outcome of acutely ill, hospitalized patients with minimal troponin I increase with normal creatine phosphokinase MB fraction.
We identified 64 patients retrospectively from our database with minimal troponin I increase and normal creatine phosphokinase MB fraction hospitalized between November 1998 and April 2000. Discharged patients were questioned about re-hospitalization for myocardial infarction, unstable coronary syndrome, congestive heart failure and percutaneous coronary intervention by means of a structured questionnaire. For those patients who died during hospitalization, data were collected from hospital records. For patients who died at home or at a different institution, a surviving relative completed the questionnaire. Primary outcomes were death, myocardial infarction and the need for revascularization or re-hospitalization.
Composite endpoint of death, myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting and re-hospitalization for cardiac cause occurred in 35.95% of patients within 1 year.
There is a significant composite event rate of death, myocardial infarction or re-hospitalization for cardiac causes in acutely ill, hospitalized patients with normal creatine phosphokinase MB fraction and minimally elevated troponin I, regardless of the cause for hospitalization.
在急性冠状动脉综合征患者中,心肌肌钙蛋白和肌酸磷酸激酶同工酶MB水平升高均具有预后和诊断价值。然而,在住院患者中,心肌生物标志物是在包括但不限于急性冠状动脉综合征在内的多种临床情况下进行检测的。此外,这些患者可能肌钙蛋白水平升高而肌酸磷酸激酶同工酶MB水平无升高。
评估急性病住院患者肌钙蛋白I轻度升高而肌酸磷酸激酶同工酶MB正常时的心血管结局。
我们从数据库中回顾性识别出1998年11月至2000年4月期间住院的64例肌钙蛋白I轻度升高且肌酸磷酸激酶同工酶MB正常的患者。通过结构化问卷对出院患者询问因心肌梗死、不稳定型冠状动脉综合征、充血性心力衰竭和经皮冠状动脉介入治疗再次住院的情况。对于住院期间死亡的患者,从医院记录中收集数据。对于在家中或其他机构死亡的患者,由幸存亲属完成问卷。主要结局为死亡、心肌梗死以及血运重建或再次住院的需求。
1年内35.95%的患者出现了死亡、心肌梗死、经皮冠状动脉介入治疗或冠状动脉搭桥术以及因心脏原因再次住院的复合终点事件。
无论住院原因如何,肌酸磷酸激酶同工酶MB正常且肌钙蛋白I轻度升高的急性病住院患者存在显著的死亡、心肌梗死或因心脏原因再次住院的复合事件发生率。